WTAP Antibody [E21M11] Datasheet

Biological Description

Specificity	WTAP Antibody [E21M11] detects endogenous levels of total WTAP protein.
Background	Wilms’ tumor 1‑associating protein (WTAP) is a nuclear regulatory subunit of the N6‑methyladenosine (m6A) methyltransferase complex that partners with the catalytic METTL3 and METTL14 subunits to control m6A deposition on a broad spectrum of coding and noncoding RNAs. WTAP contains a conserved domain that mediates interaction with METTL3 and METTL14, and it lacks intrinsic catalytic methyltransferase activity yet provides essential scaffolding that promotes the localization and stabilization of the METTL3–METTL14 complex in nuclear speckles, which are dynamic compartments enriched in splicing and mRNA‑processing factors, thereby coupling m6A modification to cotranscriptional RNA processing. WTAP modulates the efficiency of site‑specific m6A methylation on target mRNAs, which in turn influences pre‑mRNA splicing, polyadenylation, export, stability, and translation by recruiting or competing with m6A readers such as YTHDF and other RNA‑binding proteins, and it contributes to the regulation of key physiological programs, including circadian rhythms, stem‑cell renewal, and developmental gene expression. WTAP is overexpressed and its upregulation sustains elevated m6A modification of oncogenic transcripts that drive proliferation, migration, invasion, and therapy resistance, and WTAP‑dependent restructuring of the m6A epitranscriptome has been linked to enhanced cell‑migration and invasive phenotypes in glioblastoma, cholangiocarcinoma, and other malignancies.

Specificity

WTAP Antibody [E21M11] detects endogenous levels of total WTAP protein.

Background

Wilms’ tumor 1‑associating protein (WTAP) is a nuclear regulatory subunit of the N6‑methyladenosine (m6A) methyltransferase complex that partners with the catalytic METTL3 and METTL14 subunits to control m6A deposition on a broad spectrum of coding and noncoding RNAs. WTAP contains a conserved domain that mediates interaction with METTL3 and METTL14, and it lacks intrinsic catalytic methyltransferase activity yet provides essential scaffolding that promotes the localization and stabilization of the METTL3–METTL14 complex in nuclear speckles, which are dynamic compartments enriched in splicing and mRNA‑processing factors, thereby coupling m6A modification to cotranscriptional RNA processing. WTAP modulates the efficiency of site‑specific m6A methylation on target mRNAs, which in turn influences pre‑mRNA splicing, polyadenylation, export, stability, and translation by recruiting or competing with m6A readers such as YTHDF and other RNA‑binding proteins, and it contributes to the regulation of key physiological programs, including circadian rhythms, stem‑cell renewal, and developmental gene expression. WTAP is overexpressed and its upregulation sustains elevated m6A modification of oncogenic transcripts that drive proliferation, migration, invasion, and therapy resistance, and WTAP‑dependent restructuring of the m6A epitranscriptome has been linked to enhanced cell‑migration and invasive phenotypes in glioblastoma, cholangiocarcinoma, and other malignancies.

Usage Information

Application

WB, IP

Dilution

WB	IP
1:1000	1:100

Reactivity

Human, Monkey

Source

Rabbit Monoclonal Antibody

MW

55 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/36207306/
https://pubmed.ncbi.nlm.nih.gov/40948545/

Application Data

WB

Validated by Selleck

Lane 1: MOLT4, Lane 2: COS-7